Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (655 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive chorea and dementia in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; depression; hallucinations; and delusions. Eventually intellectual impairment; loss of fine motor control; athetosis; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including seizures; ataxia; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Progressive Chorea, Hereditary, Chronic (Huntington); Chronic Progressive Hereditary Chorea (Huntington); Huntington's Chorea; Chorea, Huntington's; Huntington Chorea; Chorea, Huntington; Huntington's Disease; Chorea, Chronic Progressive Hereditary (Huntington).
Where it fits in the MeSH classification
- Broader topics
- Basal Ganglia Diseases; Dementia; Chorea; Heredodegenerative Disorders, Nervous System; Cognition Disorders
Related concepts
- Chorea
- Dementia
- Depression
- Hallucinations
- Delusions
- Athetosis
- Seizures
- Ataxia
Research landscape
PubMed indexes 15,033 records tagged with the MeSH heading “Huntington Disease” (counts retrieved 2026-10-29). 2,895 of them (19.3%) were published from 2020 onward, and the busiest period so far is 2010-2019 with 4,704 records.
Reviews account for 2,724 records (18.1%) and meta-analyses for 62. Randomized controlled trials number 148 (1.0%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 4,337 |
| 2000-2009 | 3,097 |
| 2010-2019 | 4,704 |
| 2020 onward | 2,895 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 2,724 | 18.1% |
| Meta-analyses | 62 | 0.4% |
| Randomized controlled trials | 148 | 1.0% |
Method: PubMed query "Huntington Disease"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.
Reading the evidence in rare and inherited diseases
Rare conditions are difficult to study: few patients means small studies, case reports and registries are common, and randomized trials are the exception. Small samples limit precision and can exaggerate effects, and cases reported in the literature may be the most severe or unusual. Evidence from many small studies is best read together. Check how patients were identified, how many were included and how long they were followed.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Huntington's Disease: Complex Pathogenesis and Therapeutic Strategies | 2024 | Review article Design not recorded in structured metadata | 79 | cc by PMID 38612657 · DOI · PMC11011923 |
| Somatic CAG repeat expansion in blood associates with biomarkers of neurodegeneration in Huntington's disease decades before clinical motor diagnosis | 2025 | Research article Design not recorded in structured metadata | 70 | cc by PMID 39825149 · DOI · PMC11922752 |
| Base editing of trinucleotide repeats that cause Huntington's disease and Friedreich's ataxia reduces somatic repeat expansions in patient cells and in mice | 2025 | Research article Design not recorded in structured metadata | 34 | cc by PMID 40419681 · DOI · PMC12165863 |
| Huntington's disease clinical trials update: October 2025 | 2026 | Review article Design not recorded in structured metadata | 8 | cc by PMID 41295902 · DOI · PMC12847458 |
Huntington's Disease: Complex Pathogenesis and Therapeutic Strategies [1]
Abstract reading summary — source excerpts
- Opening excerpt
- Huntington's disease (HD) arises from the abnormal expansion of CAG repeats in the huntingtin gene (HTT), resulting in the production of the mutant huntingtin protein (mHTT) with a polyglutamine stretch in its N-terminus.
- Closing excerpt
- This review provides an overview of current HD treatments, discusses different therapeutic strategies, and aims to facilitate future therapeutic advancements in the field.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (141 words)
Huntington's disease (HD) arises from the abnormal expansion of CAG repeats in the huntingtin gene (HTT), resulting in the production of the mutant huntingtin protein (mHTT) with a polyglutamine stretch in its N-terminus. The pathogenic mechanisms underlying HD are complex and not yet fully elucidated. However, mHTT forms aggregates and accumulates abnormally in neuronal nuclei and processes, leading to disruptions in multiple cellular functions. Although there is currently no effective curative treatment for HD, significant progress has been made in developing various therapeutic strategies to treat HD. In addition to drugs targeting the neuronal toxicity of mHTT, gene therapy approaches that aim to reduce the expression of the mutant HTT gene hold great promise for effective HD therapy. This review provides an overview of current HD treatments, discusses different therapeutic strategies, and aims to facilitate future therapeutic advancements in the field.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 38612657 · DOI · PMC11011923
Somatic CAG repeat expansion in blood associates with biomarkers of neurodegeneration in Huntington's disease decades before clinical motor diagnosis [2]
Abstract reading summary — source excerpts
- Opening excerpt
- Huntington's disease (HD) is an autosomal dominant neurodegenerative disease with the age at which characteristic symptoms manifest strongly influenced by inherited HTT CAG length.
- Closing excerpt
- gov registration: NCT06391619 .
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (253 words)
Huntington's disease (HD) is an autosomal dominant neurodegenerative disease with the age at which characteristic symptoms manifest strongly influenced by inherited HTT CAG length. Somatic CAG expansion occurs throughout life and understanding the impact of somatic expansion on neurodegeneration is key to developing therapeutic targets. In 57 HD gene expanded (HDGE) individuals, ~23 years before their predicted clinical motor diagnosis, no significant decline in clinical, cognitive or neuropsychiatric function was observed over 4.5 years compared with 46 controls (false discovery rate (FDR) > 0.3). However, cerebrospinal fluid (CSF) markers showed very early signs of neurodegeneration in HDGE with elevated neurofilament light (NfL) protein, an indicator of neuroaxonal damage (FDR = 3.2 × 10-12), and reduced proenkephalin (PENK), a surrogate marker for the state of striatal medium spiny neurons (FDR = 2.6 × 10-3), accompanied by brain atrophy, predominantly in the caudate (FDR = 5.5 × 10-10) and putamen (FDR = 1.2 × 10-9). Longitudinal increase in somatic CAG repeat expansion ratio (SER) in blood was a significant predictor of subsequent caudate (FDR = 0.072) and putamen (FDR = 0.148) atrophy. Atypical loss of interruption HTT repeat structures, known to predict earlier age at clinical motor diagnosis, was associated with substantially faster caudate and putamen atrophy. We provide evidence in living humans that the influence of CAG length on HD neuropathology is mediated by somatic CAG repeat expansion. These critical mechanistic insights into the earliest neurodegenerative changes will inform the design of preventative clinical trials aimed at modulating somatic expansion. ClinicalTrials.gov registration: NCT06391619 .
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 39825149 · DOI · PMC11922752
Base editing of trinucleotide repeats that cause Huntington's disease and Friedreich's ataxia reduces somatic repeat expansions in patient cells and in mice [3]
Abstract reading summary — source excerpts
- Opening excerpt
- Trinucleotide repeat (TNR) diseases are neurological disorders caused by expanded genomic TNRs that become unstable in a length-dependent manner.
- Closing excerpt
- These findings demonstrate that introducing interruptions in pathogenic TNRs can mitigate a key neurological feature of TNR diseases in vivo.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (148 words)
Trinucleotide repeat (TNR) diseases are neurological disorders caused by expanded genomic TNRs that become unstable in a length-dependent manner. The CAG•CTG sequence is found in approximately one-third of pathogenic TNR loci, including the HTT gene that causes Huntington's disease. Friedreich's ataxia, the most prevalent hereditary ataxia, results from GAA repeat expansion at the FXN gene. Here we used cytosine and adenine base editing to reduce the repetitiveness of TNRs in patient cells and in mice. Base editors introduced G•C>A•T and A•T>G•C interruptions at CAG and GAA repeats, mimicking stable, nonpathogenic alleles that naturally occur in people. AAV9 delivery of optimized base editors in Htt.Q111 Huntington's disease and YG8s Friedreich's ataxia mice resulted in efficient editing in transduced tissues, and significantly reduced repeat expansion in the central nervous system. These findings demonstrate that introducing interruptions in pathogenic TNRs can mitigate a key neurological feature of TNR diseases in vivo.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 40419681 · DOI · PMC12165863
Huntington's disease clinical trials update: October 2025 [4]
Abstract reading summary — source excerpts
- Opening excerpt
- In this edition of the Huntington's Disease Clinical Trials Update, we expand on the launch of the phase II/III clinical trial of SKY-0515 from Skyhawk Therapeutics and the phase I/II clinical trial of SPK-10001 from Spark Therapeutics.
- Closing excerpt
- Finally, we provide an updated listing of all registered and ongoing clinical trials in Huntington's disease.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (113 words)
In this edition of the Huntington's Disease Clinical Trials Update, we expand on the launch of the phase II/III clinical trial of SKY-0515 from Skyhawk Therapeutics and the phase I/II clinical trial of SPK-10001 from Spark Therapeutics. We also report positive topline data from uniQure's phase I/II clinical trial of AMT-130 after 36 months of follow-up. Further updates include recent developments in Roche's tominersen programme within GENERATION HD2, progress with votoplam (PTC518) in PIVOT-HD by PTC Therapeutics and developments in the collaborative PTC Therapeutics/Novartis programme. We additionally discuss regulatory developments regarding pridopidine following the negative PROOF-HD study. Finally, we provide an updated listing of all registered and ongoing clinical trials in Huntington's disease.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41295902 · DOI · PMC12847458
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis [5]
- Research article Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities [6]
- Research article A biological classification of Huntington's disease: the Integrated Staging System [7]
- Research article Prevalence and Incidence of Huntington's Disease: An Updated Systematic Review and Meta-Analysis [8]
- Research article Mitochondrial dysfunction and oxidative stress in Alzheimer's disease, and Parkinson's disease, Huntington's disease and Amyotrophic Lateral Sclerosis -An updated review [9]
- Research article Huntington's disease: diagnosis and management [10]
References
- Tong H, Yang T, Xu S, Li X, Liu L, Zhou G, et al.. Huntington's Disease: Complex Pathogenesis and Therapeutic Strategies. . 2024. PMID 38612657 · DOI · PMC11011923
- Scahill RI, Farag M, Murphy MJ, Hobbs NZ, Leocadi M, Langley C, et al.. Somatic CAG repeat expansion in blood associates with biomarkers of neurodegeneration in Huntington's disease decades before clinical motor diagnosis. . 2025. PMID 39825149 · DOI · PMC11922752
- Matuszek Z, Arbab M, Kesavan M, Hsu A, Roy JCL, Zhao J, et al.. Base editing of trinucleotide repeats that cause Huntington's disease and Friedreich's ataxia reduces somatic repeat expansions in patient cells and in mice. . 2025. PMID 40419681 · DOI · PMC12165863
- Farag M, Tabrizi SJ, Wild EJ. Huntington's disease clinical trials update: October 2025. . 2026. PMID 41295902 · DOI · PMC12847458
- Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov Disord. 2012. PMID 22692795 · DOI
- Tabrizi SJ, Estevez-Fraga C, van Roon-Mom WMC, Flower MD, Scahill RI, Wild EJ, et al.. Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities. Lancet Neurol. 2022. PMID 35716694 · DOI · PMC7613206
- Tabrizi SJ, Schobel S, Gantman EC, Mansbach A, Borowsky B, Konstantinova P, et al.. A biological classification of Huntington's disease: the Integrated Staging System. Lancet Neurol. 2022. PMID 35716693 · DOI
- Medina A, Mahjoub Y, Shaver L, Pringsheim T. Prevalence and Incidence of Huntington's Disease: An Updated Systematic Review and Meta-Analysis. Mov Disord. 2022. PMID 36161673 · DOI · PMC10086981
- Alqahtani T, Deore SL, Kide AA, Shende BA, Sharma R, Dadarao Chakole R, et al.. Mitochondrial dysfunction and oxidative stress in Alzheimer's disease, and Parkinson's disease, Huntington's disease and Amyotrophic Lateral Sclerosis -An updated review. Mitochondrion. 2023. PMID 37269968 · DOI
- Stoker TB, Mason SL, Greenland JC, Holden ST, Santini H, Barker RA. Huntington's disease: diagnosis and management. Pract Neurol. 2022. PMID 34413240 · DOI
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-29.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.